Salt water medical uses and warm properties cured egg yolk lamp

Jagsonpal Pharma Share Price: Real-time BSE/NSE updates

Short intro :
Jagsonpal Pharma share price — a concise overview highlighting current trends, performance updates, and projected targets for 2025 and 2030.
This article gives data-backed context, screening tips, risks and FAQ to help investors and content publishers.

Data freshness note: price and fundamental figures cited below are pulled from live market pages and filings (sources cited inline). Always cross-check the exact quote time before trading.

1 — INTRODUCTION

Jagsonpal Pharmaceuticals (ticker: JAGSNPHARM / BSE: 507789) is a small-cap Indian pharmaceutical company whose stock has attracted attention after strong revenue growth and recent acquisitions. This guide compiles live price data, historical context, two forward-looking target scenarios (2025 & 2030), screener tips, and the most relevant ratios you need for SEO-rich content or investor notes. Nirmal BangMoneycontrol

SEO snippet: Overview of Jagsonpal Pharma’s market snapshot, why it matters to retail and institutional investors, and what to watch next.
LSI / Related keywords: Jagsonpal Pharmaceuticals Ltd, JAGSNPHARM price, Jagsonpal market cap, Jagsonpal Pharma news, Jagsonpal financials.

External links (for this section)

  • Jagsonpal company profile — Economic Times (authoritative company overview) — https://economictimes.indiatimes.com/jagsonpal-pharmaceuticals-ltd/stocks/companyid-4745.cms (target="_blank" rel="")
  • Recent financials & filings — Reuters company page — https://www.reuters.com/markets/companies/JGSN.NS (target="_blank" rel="")

2 — JAGSONPAL PHARMA SHARE PRICE

Short summary / SEO snippet: Real-time price, intraday range and 52-week performance snapshot for Jagsonpal Pharma (use these exact figures as of the cited pages). MoneycontrolScreener

  • Jagsonpal’s public quotes vary between data vendors, but main exchange values (NSE/BSE) are consistent. As of recent sessions, Jagsonpal Pharma has been fluctuating within the ₹240–₹260 band, while its 52-week journey extends from lows of around ₹140 to highs approaching ₹328.

Use exchange pages or trusted aggregators for the exact timestamped quote before publishing. MoneycontrolNirmal Bang

Key quick stats (sourced):

LSI / Related keywords: JAGSNPHARM live quote, Jagsonpal stock today, Jagsonpal price NSE, Jagsonpal 52 week high low.

How to present this on a page (SEO tip): use an H2 with the primary keyword exactly (“jagsonpal pharma share price”), include a live data widget or clearly timestamped price, and beneath it show 52-wk range, market cap and PE — all with citations.

External links (for this section)

  • Jagsonpal Pharma — Moneycontrol live quote and basic snapshot — https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/jagsonpalpharmaceuticals/JP02 (target="_blank" rel="nofollow"). Moneycontrol

3 — JAGSONPAL PHARMA SHARE PRICE TARGET 2025

Short summary / SEO snippet: Realistic 2025 price-target scenarios (conservative, base, optimistic) derived from trailing EPS and plausible PE multiples — explained step-by-step so editors can reuse text safely.

Because formal analyst coverage is limited, a simple, transparent approach is: multiply a realistic future EPS by reasonable pharma-sector P/E multiples to create a target range. Recent trailing EPS (TTM) used in our scenario: ~₹9.14 (fundamental snapshot). Groww

Price-target scenarios (method + numbers):

  • Method: Price ≈ EPS × P/E. (EPS = trailing 12-month EPS; choose P/E ranges based on sector and growth prospects.) Screener
  • Conservative (PE 25): EPS 9.14 × 25 ≈ ₹228.5.
  • Base (PE 30): EPS 9.14 × 30 ≈ ₹274.2.
  • Optimistic (PE 35): EPS 9.14 × 35 ≈ ₹319.9.

(Calculations are shown so you can copy them into editorial notes and confirm with latest EPS values.) GrowwScreener

Why these multiples? Small-cap pharma names often trade at a premium when growth/ROCE looks strong; choosing 25–35 P/E brackets gives a conservative→optimistic coverage range. Note: limited formal analyst coverage means market multiples can move quickly; always timestamp numbers. Simply Wall St.

LSI / Related keywords: jagsonpal price target 2025, jagsonpal 2025 forecast, jagsonpal EPS, pharma valuation method.

External links (for this section)

  • EPS & fundamentals — Groww company page (EPS figure & ratios) — https://groww.in/stocks/jagsonpal-pharmaceuticals-ltd (target="_blank" rel="nofollow"). Groww

Editor’s SEO snippet to publish: “Jagsonpal Pharma 2025 price-target range (conservative ₹228 — optimistic ₹320) based on trailing EPS and sector P/E multiples. Not investment advice.”

4 — JAGSONPAL PHARMA SHARE PRICE BSE

Short summary / SEO snippet: Official exchange identifiers — BSE code, NSE symbol and ISIN — and where to get authoritative exchange quotes for embedding or citation. Nirmal BangNSE India

Official exchange identifiers you should publish:

Where to get authoritative quotes: Always prefer the official exchange pages (NSE/BSE) for live quotes and corporate announcements — use the exchange’s “get-quotes” endpoint or official corporate filings for regulatory events. NSE IndiaBSE

LSI / Related keywords: jagsonpal bse code, jagsonpal bse listing, JAGSNPHARM ISIN.

External links (for this section)

  • NSE — Jagsonpal quotes and trade page — https://www.nseindia.com/get-quotes/equity?symbol=JAGSNPHARM (target="_blank" rel="") . NSE India

5 — JAGSONPAL PHARMA SHARE PRICE SCREENER (HOW TO SCREEN)

Short summary / SEO snippet: Use screener filters and metrics (PE, PB, ROCE, revenue growth) to decide whether Jagsonpal fits value, growth, or dividend buckets; recommended screens and where to pull ratios. ScreenerTradingView

Practical screening checklist (publishable / SEO-friendly):

  1. Profitability & returns: ROCE, ROE — Jagsonpal shows attractive ROCE/ROE relative to some peers (check Screener/Groww fundamentals). ScreenerGroww
  2. Valuation: P/E and P/B vs sector median; use 1-year forward P/E if available. Screener
  3. Revenue momentum: Year-over-year sales growth and recent quarter jumps (growth after acquisitions). Moneycontrol
  4. Insider/promoter holding: high promoter holding can reduce free float but may signal commitment. (Jagsonpal promoter holding ~67% per data vendors.) Angel One

Tools to embed on SEO pages: Screener.in for fundamental ratios (exportable tables), TradingView for embeddable charts and technical overlays, Moneycontrol/Groww for quick ratios and filings. ScreenerTradingViewMoneycontrol

LSI / Related keywords: jagsonpal screener, jagsonpal fundamentals, jagsonpal ratios, how to screen jagsonpal.

External links (for this section)

  • Screener.in — Jagsonpal fundamental snapshot and ratios — https://www.screener.in/company/JAGSNPHARM/ (target="_blank" rel="nofollow"). Screener

6 — JAGSONPAL PHARMA SHARE PRICE HISTORY

Short summary / SEO snippet: One-year and longer-term price performance, major price drivers and corporate events that shaped the trend. Cite historical data and corporate announcements. Investing.comBSE

Highlights & context:

  • 1-year / multi-year performance: Several data vendors show strong 1-year returns (example: +~70–78% YTD/1Y at some snapshots) as markets re-rated the stock amid revenue recovery. Always confirm exact % as it moves daily. The Economic Times
  • Catalyst events: the company announced acquisitions and business transfers (for example, the Yash Pharma business transfer and recent smaller cosmeceutical acquisition), which can materially affect revenue bases and investor perception. BSEStockAnalysis
  • Historical daily data & downloads: Use Yahoo Finance / Investing.com to pull daily OHLC history for charts and backtests. Yahoo FinanceInvesting.com

LSI / Related keywords: jagsonpal share price history, JAGSNPHARM historical data, jagsonpal corporate actions.

External links (for this section)

  • Historical daily prices — Yahoo Finance (downloadable CSV) — https://finance.yahoo.com/quote/JAGSNPHARM.NS/history/ (target="_blank" rel="nofollow"). Yahoo Finance

7 — JAGSONPAL PHARMA SHARE PRICE TARGET 2030

Short summary / SEO snippet: Long-term 2030 price scenarios using EPS growth assumptions and reasonable P/E ranges; transparency on assumptions and an external model match. Walletinvestor.comGroww

Scenario method & numbers: Using a simple earnings-growth projection and target P/E band provides an illustrative long-term price. Example (illustrative model):

  • Starting TTM EPS: ~₹9.14. Groww
  • Assumed EPS CAGR (2025→2030): 12% p.a. (example growth rate; change it for sensitivity). Under 12% over 5 years EPS ≈ ₹16.11. (EPS_2030 = 9.14 × (1.12)^5 ≈ 16.11). Groww
  • Apply P/E 27–30: Price range ≈ ₹435 — ₹483 by 2030 under these assumptions — broadly matching third-party long-horizon models (some automated forecasters project similar mid-400s outcomes). Walletinvestor.com

Why show ranges instead of a point estimate: Long-term targets depend heavily on realized growth rates, margin expansion and the market’s appetite for pharma names; showing a band clarifies uncertainty for readers.

LSI / Related keywords: jagsonpal 2030 target, jagsonpal long term forecast, jagsonpal future price 2030.

External links (for this section)

  • Long-range model example — WalletInvestor forecast page (automated model) — https://walletinvestor.com/bse-stock-forecast/jagsonpal-pharmaceuticals-ltd-bse-prediction (target="_blank" rel="nofollow"). Walletinvestor.com

8 — FINANCIALS, KEY RATIOS & WHAT THEY MEAN

Short summary / SEO snippet: Key ratios (P/E, P/B, ROE, ROCE, debt/equity) that matter for Jagsonpal and where to get the numbers for tables and comparison snapshots. ScreenerGroww

Key published ratios (examples from snapshots):

  • P/E (TTM): varies by source and live price — watch Moneycontrol / Screener for the latest. MoneycontrolScreener
  • P/B & Book value: book value ~₹36 per share (check current figures) — P/B is therefore derived from live price / book. Screener
  • ROCE / ROE: Jagsonpal shows double-digit ROCE and ROE metrics in many snapshots, a favorable sign for capital efficiency. Screener
  • Debt: low net debt historically (company reported internal accrual use for acquisitions), which is important for stability. BSE

How to format a financials block for SEO pages: For BSE financial sections designed for SEO, structure a compact table covering metrics like Price, Market Cap, P/E, P/B, ROCE, ROE, EPS (TTM), and Dividend Yield. Always add a timestamp such as ‘Data updated on [date/time] — source: [link]’ for clarity.

LSI / Related keywords: jagsonpal financials, jagsonpal ratios, JAGSNPHARM ROE ROCE, jagsonpal debt to equity.

External links (for this section)

  • Detailed P&L and quarterly updates — Moneycontrol financials page — https://www.moneycontrol.com/financials/jagsonpalpharmaceuticals/profit-lossVI/jp02 (target="_blank" rel="nofollow"). Moneycontrol

9 — RISKS, CATALYSTS & HOW TO TRACK THE STOCK

Short summary / SEO snippet: List of principal risks and upcoming catalysts to monitor — regulatory changes, acquisitions, product approvals and quarterly earnings that can move the stock. BSEThe Economic Times

Top risks to mention (for editorial/SEO use):

  • Regulatory / pricing risk: pharma margins depend on product approvals and pricing environment.
  • Execution risk for acquisitions: timely integration and realization of synergies. (Recent BTA signals material deals.) BSE
  • Market-sentiment risk: small-cap stocks can swing widely on flows and relative lack of analyst coverage. Simply Wall St.

Key catalysts to follow: quarterly earnings releases, corporate filings on acquisitions, new product launches, and promoter shareholding disclosures. Use the BSE corporate announcements feed for instant regulatory filings. BSEThe Economic Times

How to track in real time: set exchange alerts (NSE/BSE), follow the company’s corporate announcements page and use alerting tools from Moneycontrol/TradingView/Screener. NSE IndiaTradingView

LSI / Related keywords: jagsonpal risks, jagsonpal catalysts, how to monitor jagsonpal, corporate announcements jagsonpal.

External links (for this section)

  • BSE corporate filing (example acquisition announcement PDF) — https://www.bseindia.com/xml-data/corpfiling/AttachHis/4e8819fe-ac27-486d-a702-78c42da4ea1b.pdf (target="_blank" rel="nofollow"). BSE

10 — FAQs (Expanded)

Short summary / SEO snippet: A compact FAQ block answers the most searched questions and helps capture “people also ask” traffic.

Q1 — What is the current Jagsonpal Pharma share price?
A: Use the official exchange pages (NSE/BSE) or leading market aggregators (Moneycontrol, Screener, Groww) for the real-time quote; examples cited above. (Always timestamp.) MoneycontrolNSE India

Q2 — What is the BSE code for Jagsonpal Pharma?
A: 507789 (BSE scrip) and NSE symbol JAGSNPHARM; ISIN INE048B01035. Nirmal Bang

Q3 — What are realistic price targets for 2025 and 2030?
A: Scenario ranges shown earlier: 2025 (conservative ₹228 — optimistic ₹320) and 2030 illustrative band ~₹435–₹483 under an assumed 12% EPS CAGR and 27–30 P/E. These are model outputs, not recommendations. GrowwWalletinvestor.com

Q4 — Does Jagsonpal have analyst coverage?
A: Formal sell-side coverage appears limited; platforms like SimplyWall show sparse analyst forecasts — rely on fundamentals and your model. Simply Wall St.

Q5 — Should I buy Jagsonpal Pharma?
A: This is not investment advice. Use the screener checklist above, consider risk tolerance, and consult a licensed advisor.

Additional SEO FAQ questions to consider adding on the page:

  • How has Jagsonpal Pharma performed in the last 12 months? The Economic Times
  • What are Jagsonpal’s earnings per share and dividend history? TradingView
  • Which peers should Jagsonpal be compared with in valuation screens?

External links (for this section)

  • Jagsonpal historicals and downloads — Investing.com — https://www.investing.com/equities/jagson-pal-pharmaceuticals-ltd-historical-data (target="_blank" rel="nofollow"). Investing.com

CONCLUSION

Jagsonpal Pharma remains an interesting small-cap pharma play: the stock has shown notable price appreciation in the past year, driven by recovery in sales and strategic deals. Because formal analyst coverage is limited, transparent scenario models (EPS × P/E) and careful screening of ROCE/ROE, revenue growth and corporate filings are the best way to create defensible 2025 and 2030 targets for content and investor notes. Always add clear timestamps, source citations and a short “not investment advice” disclaimer when publishing. ScreenerBSE

External links (for the conclusion / general resources)

  • Jagsonpal official website & corporate filings — https://www.jagsonpal.com/ (target="_blank" rel="nofollow"). Jagsonpal

 

The Medical and Pharmaceutical Industry